Trial closed April 2022.
Study to Evaluate the Safety and Efficacy of Rabacfosadine, Vincristine, Cyclophosphamide, Doxorubicin and Prednisone in Dogs with Untreated Lymphoma
Purposes of the study:
- Evaluate the effectiveness and safety of the addition of rabacfosadine to a chemotherapy protocol containing doxorubicin, vincristine, cyclophosphamide and prednisone (CHOP) in dogs with previously untreated, spontaneous, multicentric lymphoma
Primary Eligibility Criteria:
- Dogs with newly diagnosed, multicentric lymphoma
- No prior chemotherapy; one-week washout from steroid treatment
- Must have good function of liver and kidneys, and be free of severe underlying disease
- No history of pulmonary fibrosis or chronic lung disease; no West Highland White Terriers
- Pets must come to CSU for all visits related to the clinical trial
- Dogs will receive four infusions each of rabacfosadine, doxorubicin, and vincristine scheduled at specific intervals over an 18-week period. During this time, owners will also be administering oral chemotherapy drugs (cyclophosphamide and prednisone).
- Weekly visits (except week 14) will be required for lab work and/or chemotherapy administration. Four of those visits may be conducted by your regular veterinarian as they will be for lab work only.
- Monthly rechecks are required after completion of chemotherapy; chest x-rays done every other month are strongly recommended
- To make and keep all appointments for the study protocol
- Must be comfortable administering oral medications at home
- Study will pay for the costs of rabacfosadine drug only
- The owner is responsible for costs of tests needed to confirm study eligibility as well as for all costs related to chemotherapy other than the cost of the rabacfosadine drug, including costs of treatment of side effects related to treatment
- Owners are responsible for the costs associated with rabacfosadine administration